文献速递乳腺癌泌尿男性生殖肿瘤消化系统肿瘤

男性BRCA1/2致病性变异携带者的癌症谱特征:CIMBA研究结果

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
PubMed 文献 · JAMA Oncol · 2020-01-01

该回顾性队列研究纳入来自33个国家53个研究组的6902名男性BRCA1/2致病性变异携带者,比较BRCA1与BRCA2携带者的癌症谱和频率。结果显示BRCA2携带者发生任何癌症、多原发肿瘤、乳腺癌、前列腺癌和胰腺癌的概率更高,而结直肠癌概率更低。这些数据可能为未来BRCA1/2相关癌症监测建议提供依据。

要点

  • 男性BRCA2携带者发生任何癌症的概率显著高于BRCA1携带者(OR 3.23)。
  • BRCA2携带者发生乳腺癌、前列腺癌和胰腺癌的概率更高,结直肠癌概率更低。
  • 多原发肿瘤(2种或3种)与BRCA2携带状态显著相关。

核心结论

  • 男性BRCA2与BRCA1致病性变异携带者之间存在显著的癌症谱差异。
  • 这些数据可能为未来BRCA1/2相关癌症监测建议提供信息,并指导未来估计男性BRCA1/2携带者癌症风险的前瞻性研究。

研究设计与样本

  • 回顾性队列研究,纳入6902名男性,包括3651名BRCA1和3251名BRCA2致病性变异携带者,年龄大于18岁。
  • 研究对象来自1966年至2017年期间53个研究组在33个国家通过CIMBA协作招募的癌症遗传学诊所。
  • 收集临床数据和病理特征,使用逻辑回归分析,BRCA1/2状态为结局,癌症诊断为独立预测因子,所有OR均调整年龄、原籍国和首次访谈日历年。

主要发现

  • 在6902名男性中(中位年龄51.6岁,范围18-100),1376名男性(19.9%)诊断了1634例癌症,其中多数(922/1376,67%)为BRCA2携带者。
  • 患有任何癌症与更高的BRCA2而非BRCA1携带概率相关(OR 3.23;95% CI 2.81-3.70;P < .001)。
  • 发生2种原发肿瘤(OR 7.97;95% CI 5.47-11.60;P < .001)和3种原发肿瘤(OR 19.60;95% CI 4.64-82.89;P < .001)与更高的BRCA2携带概率相关。
  • 乳腺癌(OR 5.47;95% CI 4.06-7.37;P < .001)和前列腺癌(OR 1.39;95% CI 1.09-1.78;P = .008)频率较高与更高的BRCA2携带概率相关。
  • 在乳腺癌和前列腺癌以外的癌症中,胰腺癌与更高的BRCA2携带概率相关(OR 3.00;95% CI 1.55-5.81;P = .001),结直肠癌与更低的BRCA2携带概率相关(OR 0.47;95% CI 0.29-0.78;P = .003)。

临床怎么用

  • 临床遗传咨询中应关注男性BRCA2携带者更高的多原发肿瘤及乳腺癌、前列腺癌、胰腺癌风险。
  • 对男性BRCA1/2携带者的监测策略可考虑根据BRCA基因类型进行差异化调整。

局限性

  • 回顾性队列设计可能存在选择偏倚和信息偏倚。
  • 数据来自癌症遗传学诊所,可能不能完全代表一般人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. OBJECTIVE: To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 PV carriers. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 6902 men, including 3651 BRCA1 and 3251 BRCA2 PV carriers, older than 18 years recruited from cancer genetics clinics from 1966 to 2017 by 53 study groups in 33 countries worldwide collaborating through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Clinical data and pathologic characteristics were collected. MAIN OUTCOMES AND MEASURES: BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview. RESULTS: Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P < .001), as well as developing 2 (OR, 7.97; 95% CI, 5.47-11.60; P < .001) and 3 (OR, 19.60; 95% CI, 4.64-82.89; P < .001) primary tumors. A higher frequency of breast (OR, 5.47; 95% CI, 4.06-7.37; P < .001) and prostate (OR, 1.39; 95% CI, 1.09-1.78; P = .008) cancers was associated with a higher probability of being a BRCA2 PV carrier. Among cancers other than breast and prostate, pancreatic cancer was associated with a higher probability (OR, 3.00; 95% CI, 1.55-5.81; P = .001) and colorectal cancer with a lower probability (OR, 0.47; 95% CI, 0.29-0.78; P = .003) of being a BRCA2 PV carrier. CONCLUSIONS AND RELEVANCE: Significant differences in the cancer spectrum were observed in male BRCA2, compared with BRCA1, PV carriers. These data may inform future recommendations for surveillance of BRCA1/2-associated cancers and guide future prospective studies for estimating cancer risks in men with BRCA1/2 PVs.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Silvestri V, Leslie G, Barnes DR, et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020. PMID: 32614418. doi:10.1001/jamaoncol.2020.2134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。